Lonza | LONN - Selling And Administration Expenses


Lonza reported CHF20.7M in Selling and Administration Expenses for its fiscal semester ending in December of 2022.





Selling And Administration Expenses Change Date
Akzo Nobel EUR 816M 17M Sep/2026
Alcon AG USD 964M 82M Jun/2026
AstraZeneca USD 5.8B 735M Jun/2026
BASF EUR 2.16B 123M Sep/2026
Bayer EUR 3.96B 267M Jun/2026
Beiersdorf EUR 282M 11M Jun/2026
Covestro EUR 445M 8M Dec/2025
Demant DKK 7.09B 1B Jun/2026
Fresenius EUR 760M 17M Jun/2026
Fresenius Medical Care EUR 736.01M 12.99M Jun/2026
Geberit CHF 226M 38.6M Mar/2025
Genmab DKK 205M 39M Jun/2026
Givaudan CHF 561M 25M Dec/2025
GlaxoSmithKline GBP 2.16B 39M Sep/2026
GN Store Nord DKK 805M 42M Jun/2026
Hikma Pharmaceutical USD 288M 149M Dec/2025
Johnson Matthey GBP 119M 51M Jun/2026
Merck EUR 1.57B 49M Jun/2026
Novartis USD 3.24B 101M Jun/2026
Philips EUR 1.21B 23M Jun/2026
Roche Holding CHF 6.37B 908M Jun/2026
Sanofi EUR 2.63B 307M Jun/2026
Smith & Nephew USD 1.45B 29M Jun/2026
Solvay EUR 123M 8M Jun/2026
UCB EUR 1.47B 193M Dec/2025